Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Total Current Liabilities (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Total Current Liabilities for 7 consecutive years, with $15.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 1.21% year-over-year to $15.1 million, compared with a TTM value of $15.1 million through Dec 2025, up 1.21%, and an annual FY2025 reading of $15.1 million, up 1.21% over the prior year.
  • Total Current Liabilities was $15.1 million for Q4 2025 at aTYR PHARMA, down from $15.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $16.4 million in Q4 2023 and bottomed at $4.5 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $11.7 million, with a median of $12.6 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities plummeted 57.39% in 2021, then soared 130.53% in 2022.
  • Year by year, Total Current Liabilities stood at $6.0 million in 2021, then skyrocketed by 130.53% to $13.9 million in 2022, then increased by 18.42% to $16.4 million in 2023, then fell by 8.83% to $15.0 million in 2024, then grew by 1.21% to $15.1 million in 2025.
  • Business Quant data shows Total Current Liabilities for ATYR at $15.1 million in Q4 2025, $15.7 million in Q3 2025, and $15.5 million in Q2 2025.